New Data from Cancer Center of Kansas Illuminate Findings in Breast Cancer (Clinical Utility of Genomic Recurrence Risk Stratification In Early, Hormone-receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Breast Cancer:...).

Předmět:	HORMONE receptor positive breast cancer CANCER relapse EPIDERMAL growth factor receptors BREAST cancer
Zdroj:	Women's Health Weekly; 5/9/2023, p484-484, 1p
Abstrakt:	Keywords: Wichita; State:Kansas; United States; North and Central America; Breast Cancer; Business; Cancer; Drugs and Therapies; Genetics; Growth Factor Receptors; Health and Medicine; Hormones; Membrane Proteins; Oncology; Peptide Receptors; Risk and Prevention; Women's Health EN Wichita State:Kansas United States North and Central America Breast Cancer Business Cancer Drugs and Therapies Genetics Growth Factor Receptors Health and Medicine Hormones Membrane Proteins Oncology Peptide Receptors Risk and Prevention Women's Health 484 484 1 05/08/23 20230509 NES 230509 2023 MAY 9 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Data detailed on Oncology - Breast Cancer have been presented. RNA-based genomic risk assessment estimates chemotherapy benefit in patients with hormone-receptor positive (HR +)/Human Epidermal Growth Factor 2-negative (ERBB2-) breast cancer (BC). [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu